ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) SVP Sells $60,000.00 in Stock

ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) SVP Krista Davis sold 1,000 shares of the business’s stock in a transaction dated Wednesday, December 11th. The stock was sold at an average price of $60.00, for a total value of $60,000.00. Following the transaction, the senior vice president now directly owns 49,059 shares of the company’s stock, valued at $2,943,540. The trade was a 2.00 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available through this hyperlink.

ANI Pharmaceuticals Stock Performance

Shares of ANIP stock opened at $56.56 on Friday. The company has a current ratio of 2.74, a quick ratio of 1.97 and a debt-to-equity ratio of 1.52. ANI Pharmaceuticals, Inc. has a fifty-two week low of $51.24 and a fifty-two week high of $70.81. The stock has a 50 day moving average price of $58.04 and a two-hundred day moving average price of $60.36.

ANI Pharmaceuticals (NASDAQ:ANIP) last announced its quarterly earnings data on Friday, November 8th. The specialty pharmaceutical company reported $1.34 earnings per share for the quarter, beating the consensus estimate of $1.09 by $0.25. ANI Pharmaceuticals had a positive return on equity of 15.87% and a negative net margin of 1.28%. The firm had revenue of $148.30 million during the quarter, compared to the consensus estimate of $144.37 million. During the same quarter in the previous year, the company posted $1.05 earnings per share. The business’s revenue was up 12.5% on a year-over-year basis. As a group, research analysts forecast that ANI Pharmaceuticals, Inc. will post 3.87 earnings per share for the current year.

Analysts Set New Price Targets

Several brokerages have issued reports on ANIP. Truist Financial upped their target price on ANI Pharmaceuticals from $60.00 to $62.00 and gave the stock a “hold” rating in a research note on Tuesday, October 22nd. Raymond James upped their target price on ANI Pharmaceuticals from $81.00 to $83.00 and gave the stock an “outperform” rating in a research note on Wednesday, September 18th. StockNews.com lowered ANI Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Saturday, September 7th. Leerink Partnrs raised ANI Pharmaceuticals to a “strong-buy” rating in a research note on Wednesday. Finally, Leerink Partners began coverage on ANI Pharmaceuticals in a research note on Wednesday. They issued an “outperform” rating and a $80.00 target price for the company. Two investment analysts have rated the stock with a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $77.71.

Institutional Trading of ANI Pharmaceuticals

Several hedge funds and other institutional investors have recently bought and sold shares of the stock. Innealta Capital LLC bought a new position in shares of ANI Pharmaceuticals during the second quarter valued at approximately $65,000. Ridgewood Investments LLC bought a new position in shares of ANI Pharmaceuticals during the second quarter valued at approximately $85,000. Zurcher Kantonalbank Zurich Cantonalbank raised its holdings in shares of ANI Pharmaceuticals by 24.2% during the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 2,971 shares of the specialty pharmaceutical company’s stock valued at $177,000 after acquiring an additional 579 shares in the last quarter. XTX Topco Ltd bought a new position in shares of ANI Pharmaceuticals during the second quarter valued at approximately $207,000. Finally, HighTower Advisors LLC bought a new position in shares of ANI Pharmaceuticals during the third quarter valued at approximately $222,000. Institutional investors own 76.05% of the company’s stock.

About ANI Pharmaceuticals

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.